Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sareum Holdings plc
DescriptionTyrosine kinase 2 (TYK2) inhibitor
Molecular Target Tyrosine kinase 2 (TYK2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL); Treat B-cell acute lymphoblastic leukemia (ALL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today